Oral Transmucosal Drug Delivery Device; P.K. Raghuprasad; Odessa, TX; U.S. Patent # 9,987,196; June 5, 2018.
The present invention provides a unique solution that will enable a variety of medicines to be self- administered transmucosally using a unique drug delivery system. A drug delivery device has a support structure and a medicine-laden member attached to the support structure. The device can be placed in the mouth preferably over the teeth and along the gums of a wearer. Upon exposing the medicine-laden member to saliva, it allows the medicament to migrate into the mouth under the tongue where it is absorbed into the mucous membrane and transmitted into the bloodstream.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Higher Order Multiple Emulsions; J. Brujic and M. Haase; New York University, US; U.S. Patent # 9,981,237; May 29, 2018.
The patent describes a new drug delivery vehicle having multiple emulsions with an “onion” topology. Multiple emulsion can be made up of droplets which encapsulate layers of oil and water from continuous phase. Active drug can be sequestered inside the inner droplets and subsequently released. Multiple emulsions can be prepared by microfluidics but the control over the design is limited because of unknown creation. Thus, these formulations are unsuitable for large-scale production because the number and size of the inner layers are determined by microfluidic flows.
Ophthalmic Drug Delivery System Containing Phospholipid and Cholesterol; S.F. Shih, P.C. Chang, Y.L. Tseng, L.S.S. Guo and K. Hong; Taiwan Liposome Co., Taiwan and TLC Biopharmaceuticals, US; U.S. Patent # 9,987,360; June 5, 2018.
Therapeutic agents administered to the eye systemically do not reach sufficient amounts due to slow blood circulation. Intravitreal injections can overcome this issue, but the drug stays at the vicinity for a short time, and repetitive intravitreal injections are not desired. Drug delivery systems containing phospholipids and cholesterol significantly prolonged the lifetime of Avastin® or other therapeutic agents. The formulation contained two phospholipids and cholesterol. The drug with excipients are first lyophilized. Prior to administration, the lyophilized powder is mixed with an aqueous solution to produce a solution or a suspension and administered.
Formulations for Tailored Drug Release; G. Mani, S. Lamichhane, J. Anderson, T. Remund, and P.W. Kelly; South Dakota Board of Regents and Sanford Health, US; U.S. Patent # 10,004,831; June 26, 2018.
One major problem with drug eluting medical devices (Ex. Drug eluting balloons) is that 80% of the drug is lost before the balloon is inflated at the diseased site and the concentration of the drug at the target site may be too low to be effective. This may cause systemic toxicity. This patent provides formulations disposed on a medical device comprising of about 10%-25% w/v of poly (ethylene oxide) polymer, a therapeutic disposed within the formulation and an inert polymer layer disposed atop the formulation. The polymer provides for release of about 1%-30% of the therapeutic within 1 minute and about 50% -100% of the therapeutic within 4-12 minutes after introduction of the formulation into physiological conditions.
Self-Lubricating Medical Syringes; F.T. Gertz, J. Noolandi, R.J. Schultheis, and D.A. Wilcox; ZebraSci, Inc., US; U.S. Patent # 9,999,731; June 19,2018.
Medical syringes are used to inject a fluid inside human body. It has a plunger, which is pushed along the inside of the syringe barrel. It then moves the fluid through a needle inside the body. Lubrication of the inside surface of the syringe barrel is important to reduce the friction between the plunger and the inner surface of the syringe barrel and ensure effective injection of fluid. This invention provides self-lubricating syringes with a plunger having a distinctive compressible porous cylinder, which can be infused with a lubricant and is sandwiched in between a proximal and distal rubber tip. This self-lubricating medical syringe will compensate for any missing lubricant along the inner surface of the syringe barrel and ensure uniform motion of the plunger.
Oral Pharmaceutical Composition of Isotretinoin; R. Rao, A.K. Fanda, S.K. Jain and R.B. Singh; Sun Pharma, India, U.S. Patent # 9,999,606; June 19, 2018.
Pharmacodynamic effects of an oral pharmaceutical formulation depend on its bioavailability at the site of activity. Aqueous solubility is a key factor affecting bioavailability of an active ingredient. Present invention provides a composition and process for preparing oral pharmaceutical composition of isotretinoin. The composition covered in this invention uses meglumine, a surfactant, a surface stabilizer and a carrier substrate in the composition to enhance bioavailability of isotretinoin. The invention also correlates enhanced bioavailability to dose reduction of isotretinoin. Reducing dose is beneficial as isotretinoin has teratogenic effects.
Oxygen-Absorbing Medical Multilayer Container and Method for Storing Biological Medicine; T. Kashiba, S. Ogawa, S. Arakawa, and K. Usuda; Mistubishi Gas Chemical Company, Japan; U.S. Patent # 9,994,382; June 12, 2018.
Present invention discloses a multilayer prefilled syringe that helps to protect biological medicinal products from oxidation during storage. Prefilled syringes are disposable syringes loaded with medicinal product. The multilayered prefilled syringe solves the oxidation problem by using layers of a thermoplastic resin, an oxygen absorbing composition and a second thermoplastic resin. This invention performs excellently in oxygen absorbing, oxygen barrier and water vapor barrier performance in long term storage of biological medicine compared to that of containers available in the market.